← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 CareDx CDNA $3.3B	254	+9	+4%	$4.93B
27	27 Fulgent Genetics FLGT $559M	254	-2	-0.8%	$987M
28	28 Twist Bioscience TWST $8.81B	245	+5	+2%	$6.4B
29	29 Ultragenyx Pharmaceutical RARE $1.45B	242	-13	-5%	$6.24B
30	30 DELISTED bluebird bio BLUE	232	+3	+1%	$1.7B
31	31 Adaptive Biotechnologies ADPT $3.85B	231	-18	-7%	$4.8B
32	32 Beam Therapeutics BEAM $2.43B	231	+21	+10%	$5.86B
33	33 Veracyte VCYT $3.52B	215	-20	-9%	$2.91B
34	34 Vericel Corp VCEL $2.06B	205	0	0%	$2.57B
35	NSTG 35 DELISTED NanoString Technologies, Inc. NSTG	203	+6	+3%	$3.19B
36	36 BridgeBio Pharma BBIO $12.9B	201	+2	+1%	$8.7B
37	37 Myriad Genetics MYGN $399M	201	+4	+2%	$2.31B
38	38 DELISTED SANGAMO THERAPEUTICS INC SGMO	197	-6	-3%	$912M
39	39 Maravai LifeSciences MRVI $1.03B	196	+52	+36%	$4.77B
40	40 PTC Therapeutics PTCT $4.98B	183	-25	-12%	$3.14B
41	41 Allogene Therapeutics ALLO $453M	182	+13	+8%	$2.25B
42	42 DELISTED DermTech, Inc. Common Stock DMTK	176	+7	+4%	$846M
43	43 Regenxbio RGNX $457M	172	-12	-7%	$1.3B
44	44 uniQure QURE $1.52B	156	+1	+0.6%	$1.11B
45	45 Bionano Genomics BNGO $15.4M	152	+42	+38%	$548M
46	46 Precigen PGEN $2.41B	150	-16	-10%	$926M
47	47 Rocket Pharmaceuticals RCKT $254M	150	-23	-13%	$2.74B
48	48 Atara Biotherapeutics ATRA $95.2M	145	-6	-4%	$1.34B
49	ATHX 49 DELISTED Athersys, Inc. Common Stock ATHX	140	+1	+0.7%	$73.2M
50	50 Personalis PSNL $1.69B	136	+2	+1%	$808M